Investigating the Epigenetic Role of lncRNAs in Patients with Diffuse B-cell Lymphomas

Subject Areas : Journal of Animal Biology

Milad Shahsavari ¹ , Sedigheh Arbabian ² , ّFarzaneh Hosseini ³ , محمدرضا رضوی ^{4 *}

1 - Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran
2 - Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran
3 - Department of Microbiology, Islamic Azad University, Tehran North Branch Tehran, Iran
4 - Microbiology Research Center, 69 Pasteur Avenue. 1316943551 Tehran, Iran

Received: 2023-12-03 Accepted : 2024-01-01 Published : 2025-01-12

Keywords: Lymphoma, DLBCL, Epigenetics, Cancer,

Abstract :

Diffuse large B-cell lymphoma (DLBCL) is a type of lymphoma that accounts for approximately 25-35% of all non-Hodgkin's lymphomas. The standard treatment for DLBCL is the R-CHOP regimen, which increases the five-year overall survival of patients, but 30–50% of patients do not respond to this therapy. Recently, a novel combination of lenalidomide plus R-CHOP has been investigated for the treatment of DLBCL. Recent studies have pointed to the potential impact of epigenetic changes in the occurrence and development of most cancers, especially DLBCL. In this study, the expression changes of two lncRNAs in patients with DLBCL were bioinformatically investigated and the relationship between the lncRNAs HOXA Transcript at the Distal Tip and Plasmacytoma Variant Translocation 1 was examined, and their impact on related signaling pathways was carefully evaluated. Finally, we showed the proteins that interact with both lncRNAs using Venn diagrams. In this study, the expression level of lncRNA in patients with DLBCL was bioinformatically analyzed and the results showed that the HOXA Transcript At The Distal Tip and Plasmacytoma Variant Translocation 1 genes were upregulated. These results can be useful in gene expression research and molecular alterations.

 

References:


Wang X, Hong Y, Meng S, Gong W, Ren T, Zhang T, et al. A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. Clin Immunol. 2022;243:109105. 2. Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;2016(1):366-78. 3. Desai SH, LaPlant B, Macon WR, King RL, Wang Y, Inwards DJ, et al. Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer J. 2021;11(9):160. 4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11. 5. Panda D, Das N, Thakral D, Gupta R. Genomic landscape of mature B-cell non-Hodgkin lymphomas — an appraisal from lymphomagenesis to drug resistance. Journal of the Egyptian National Cancer Institute. 2022;34(1):52. 6. Bakhshi TJ, Georgel PT. Genetic and epigenetic determinants of diffuse large B-cell lymphoma. Blood Cancer J. 2020;10(12):123. 7. Lu S, Zeng L, Mo G, Lei D, Li Y, Ou G, et al. Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p. PLoS One. 2023;18(11):e0294729. 8. Ghafouri-Fard S, Dashti S, Taheri M. The HOTTIP (HOXA transcript at the distal tip) lncRNA: Review of oncogenic roles in human. Biomed Pharmacother. 2020;127:110158. 9. Onagoruwa OT, Pal G, Ochu C, Ogunwobi OO. Oncogenic Role of PVT1 and Therapeutic Implications. Front Oncol. 2020;10:17. 10. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Research. 2019;47(W1):W556-W60. 11. Kang J, Tang Q, He J, Li L, Yang N, Yu S, et al. RNAInter v4.0: RNA interactome repository with redefined confidence scoring system and improved accessibility. Nucleic Acids Res. 2022;50(D1):D326-d32. 12. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638-d46. 13. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27-30. 14. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12-23. 15. Shimkus G, Nonaka T. Molecular classification and therapeutics in diffuse large B-cell lymphoma. Frontiers in Molecular Biosciences. 2023;10. 16. Lu T, Zhang J, Xu-Monette ZY, Young KH. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Experimental Hematology & Oncology. 2023;12(1):72. 17. Jiang Y, Melnick A. The epigenetic basis of diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):86-96. 18. Baylin SB, Jones PA. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016;8(9). 19. Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018;131(21):2307-19. 20. Huang X, Qian W, Ye X. Long Noncoding RNAs in Diffuse Large B-Cell Lymphoma: Current Advances and Perspectives. Onco Targets Ther. 2020;13:4295-303. 21. Habieb MSE, Goher SF, El-Torgman A-EA-E, El Sayed IET, Abd-Elfattah NZA. Biomedical impact of the expression of HOX locus-associated LncRNAs HOTAIR and HOTTIP in diffuse large B cell lymphoma. Human Gene. 2022;34:201112. 22. Yang R, Shao T, Long M, Shi Y, Liu Q, Yang L, et al. Long noncoding RNA PVT1 promotes tumor growth and predicts poor prognosis in patients with diffuse large B-cell lymphoma. Cancer Commun (Lond). 2020;40(10):551-5. 23. Duns G, Winkle M, Chong L, Ennishi D, Morin RD, Diepstra A, et al. Long non-coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B-cell lymphoma. British Journal of Haematology. 2023;202(2):440-4. 24. Vishnoi K, Viswakarma N, Rana A, Rana B. Transcription Factors in Cancer Development and Therapy. Cancers (Basel). 2020;12(8). 25. Muste Sadurni M, Saponaro M. Deregulations of RNA Pol II Subunits in Cancer. Applied Biosciences [Internet]. 2023; 2(3):[459-76 pp.]. 26. Frigault MM, Mithal A, Wong H, Stelte-Ludwig B, Mandava V, Huang X, et al. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription. Cancer Res Commun. 2023;3(11):2268-79.